Virafin for moderate Covid 19

April 26, 2021

The Drugs Controller General of India (DGCI) on Friday approved the emergency use for Zydus Cadila’s Pegylated Interferon alpha-2b ‘Virafin’ for treating moderate COVID-19 infection for adults. Zydus Cadila announced that it has received emergency use approval from DCGI to use Virafin for the treatment of moderate COVID-19 infections. As per the report, a single-dose subcutaneous regimen of the drug will make the treatment of COVID-19 more convenient. The company had said that if administered early on during COVID-19, Virafin may help patients recover faster and avoid much of the complications. It will be available on the prescription of a medical specialist.

Virafin for moderate Covid 19

RELATED NEWS

New Bill seeks to eliminate rabies and regulate dog ownership in Sri Lanka

Screen time rising among Sri Lankan preschool children, Health Ministry warns

China to deploy meteorological early-warning system in Sri Lanka

Government moves to ease prison overcrowding as remand population falls, Justice Minister says

New Bill seeks to eliminate rabies and regulate dog ownership in Sri Lanka

Screen time rising among Sri Lankan preschool children, Health Ministry warns

China to deploy meteorological early-warning system in Sri Lanka

The Easter Sunday Terror attacks Verdict: What’s Next?

Government moves to ease prison overcrowding as remand population falls, Justice Minister says

Man arrested over alleged transfer of Rs. 24.85 billion in foreign currency abroad

Court hands 200-260 year jail terms over 2019 Easter attacks

15 found guilty in Sri Lanka Easter Sunday attacks trial

Supreme Court says 22nd Amendment does not require referendum